show more articles
In future, patients should have access to innovative medicines on the day the product is authorised by Swissmedic («Day 0»).
years is the increase in life expectancy in Switzerland compared to 50 years ago. Innovative drugs have made a crucial contribution to this increase.
The pharmaceutical industry in Switzerland will also need attractive framework conditions in future, including legal certainty, open export markets and the availability of labour.
People in Switzerland benefit from access to high-quality healthcare provision. However, there is still a need for action and improvement in various areas.
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2020
More about the tasks and overriding aims of Interpharma
Latest information and media contacts for media representatives